跳至主要内容
临床试验/NCT00977613
NCT00977613已完成不适用

Prospective Evaluation of Adherence to Recommended Activity Regimen in Patients Following Treatment of Stages II and III Colorectal Cancer.

Beth Israel Medical Center2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
2
主要终点
Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater

研究概览

简要总结

Given the apparent effect of 18 metabolic equivalent task-hours of activity/week in improving disease free survival in patients with treated stage 3 colon cancer and the survival benefit of exercise demonstrated in patients with stage II and III colorectal cancer, the primary objective is to evaluate compliance at 6 months with post-treatment recommendations for a minimum of 18 metabolic units of physical activity each week in patients who have completed therapy for stage 2 and stage 3 colorectal cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with histological confirmation of stage 2 or stage 3 colorectal cancer.
  • Ability to sign written informed consent.
  • WHO performance status of 2 or better.
  • No evidence of recurrent disease or death prior to second questionnaire.
  • Patients with declining physical activity within 90 days of second physical activity assessment will be excluded.
  • There are no exclusion criteria

排除标准

  • 未提供

结局指标

主要结局

Number of Participants Who Maintained an Exercise Regimen Average of 18 Metabolic Units (MET) Per Week or Greater

时间窗: 6 months

One MET is the energy expenditure for sitting quietly for 1 hour. MET scores for walking were assigned based on the pace and duration reported. For other activities, a leisurely to moderate intensity score was selected. The scores for MET-hours per week for each activity were calculated from the reported hours per week engaged in that activity multiplied by the assigned MET score, and individual activities were summed to derive a total MET-hours per week.

次要结局

  • Recurrence-free Survival(after 6 months)
  • Overall Survival(after 6 months)
  • Disease-free Survival(after 6 months)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验